For the year ending 2025-12-31.
| Income Statement | 2025-12-31 | 2024-12-31 | ||
|---|---|---|---|---|
| Revenues from licensing and sales of intellectual property | 0 | 67,425 | ||
| Research and development | 107,295 | 167,768 | ||
| Zentera in-process research and development | 0 | - | ||
| General and administrative | 37,717 | 87,115 | ||
| Non-cash items | 0 | - | ||
| Accruals | 6,990 | - | ||
| Non-cash items | 806 | - | ||
| Restructuring | 7,796 | - | ||
| Goodwill impairment | 0 | 3,736 | ||
| Total operating expenses | 152,808 | 258,619 | ||
| Loss from operations | -152,808 | -191,194 | ||
| Investment and other income, net | 16,190 | 25,504 | ||
| Net loss before income taxes | -136,618 | -165,690 | ||
| Income tax expense (benefit) | 442 | 177 | ||
| Loss on equity method investment | 0 | - | ||
| Net loss | -137,060 | -165,867 | ||
| Net loss attributable to noncontrolling interests | 0 | -28 | ||
| Net loss attributable to zentalis | -137,060 | -165,839 | ||
| Basic EPS | -1.91 | -2.33 | ||
| Diluted EPS | -1.91 | -2.33 | ||
| Basic Average Shares | 71,869,000 | 71,080,000 | ||
| Diluted Average Shares | 71,869,000 | 71,080,000 | ||
Zentalis Pharmaceuticals, Inc. (ZNTL)
Zentalis Pharmaceuticals, Inc. (ZNTL)